Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266

1.

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

Li T, Kung HJ, Mack PC, Gandara DR.

J Clin Oncol. 2013 Mar 10;31(8):1039-49. doi: 10.1200/JCO.2012.45.3753. Epub 2013 Feb 11. Review.

2.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

Shea M, Costa DB, Rangachari D.

Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30. Review.

PMID:
26620497
3.

Biomarkers for personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30. Review.

PMID:
25468140
4.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.

PMID:
20921461
5.

Personalizing therapy in advanced non-small cell lung cancer.

Villaruz LC, Burns TF, Ramfidis VS, Socinski MA.

Semin Respir Crit Care Med. 2013 Dec;34(6):822-36. doi: 10.1055/s-0033-1358552. Epub 2013 Nov 20. Review.

6.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
7.

[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].

Pécuchet N, Legras A, Laurent-Puig P, Blons H.

Ann Pathol. 2016 Jan;36(1):80-93. doi: 10.1016/j.annpat.2015.11.012. Epub 2016 Jan 20. French.

PMID:
26803564
10.

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.

J Thorac Oncol. 2012 Dec;7(12):1767-74. doi: 10.1097/JTO.0b013e3182745bcb.

11.

A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.

Hensing T, Chawla A, Batra R, Salgia R.

Adv Exp Med Biol. 2014;799:85-117. doi: 10.1007/978-1-4614-8778-4_5. Review.

PMID:
24292963
12.

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB.

Lung Cancer. 2014 Apr;84(1):39-44. doi: 10.1016/j.lungcan.2014.01.013. Epub 2014 Jan 28.

13.

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

Alden RS, Mandrekar SJ, Oxnard GR.

Chin Clin Oncol. 2015 Sep;4(3):37. doi: 10.3978/j.issn.2304-3865.2015.09.03. Review.

14.

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).

Kumarakulasinghe NB, van Zanwijk N, Soo RA.

Respirology. 2015 Apr;20(3):370-8. doi: 10.1111/resp.12490. Epub 2015 Feb 17. Review. Erratum in: Respirology. 2016 Apr;21(3):567.

15.

Personalized targeted therapy for lung cancer.

Wu K, House L, Liu W, Cho WC.

Int J Mol Sci. 2012;13(9):11471-96. doi: 10.3390/ijms130911471. Epub 2012 Sep 13. Review.

16.

Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

Passiglia F, Bronte G, Castiglia M, Listì A, Calò V, Toia F, Cicero G, Fanale D, Rizzo S, Bazan V, Russo A.

Expert Opin Biol Ther. 2015;15(11):1553-66. doi: 10.1517/14712598.2015.1071348. Epub 2015 Sep 11. Review.

PMID:
26360115
17.

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.

Gerber DE, Oxnard GR, Govindan R.

Clin Pharmacol Ther. 2015 May;97(5):447-50. doi: 10.1002/cpt.91. Epub 2015 Apr 3. Review.

18.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA.

Drugs. 2017 May;77(8):813-827. doi: 10.1007/s40265-017-0732-2. Review.

PMID:
28378229
19.
20.

Personalized therapy for non-small cell lung cancer: which drug for which patient?

Villaruz LC, Socinski MA.

Semin Thorac Cardiovasc Surg. 2011 Winter;23(4):281-90. doi: 10.1053/j.semtcvs.2012.01.001. Review.

Supplemental Content

Support Center